🥴

UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading

While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from
UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论